Holen Sie sich die Stockscreener-App
33.53
3.94%
1.27
Handel nachbörslich:
33.53
Schlusskurs vom Vortag:
$32.26
Offen:
$33.12
24-Stunden-Volumen:
1.44M
Relative Volume:
0.84
Marktkapitalisierung:
$5.35B
Einnahmen:
$705.14M
Nettoeinkommen (Verlust:
$-453.90M
KGV:
-11.03
EPS:
-3.04
Netto-Cashflow:
$-551.29M
1W Leistung:
-0.34%
1M Leistung:
+20.18%
6M Leistung:
-11.23%
1J Leistung:
-14.20%
1-Tages-Spanne:
$32.60
$33.94
1-Wochen-Bereich:
$31.66
$33.94
52-Wochen-Spanne:
$23.95
$52.34
Ionis Pharmaceuticals Inc Stock (IONS) Company Profile
Firmenname
Ionis Pharmaceuticals Inc
Sektor
Branche
Telefon
(760) 931-9200
Adresse
2855 GAZELLE COURT, CARLSBAD, CA
Vergleichen Sie IONS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IONS
Ionis Pharmaceuticals Inc
|
33.53 | 5.35B | 705.14M | -453.90M | -551.29M | -3.04 |
|
VRTX
Vertex Pharmaceuticals Inc
|
439.37 | 128.45B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
575.63 | 65.17B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
560.90 | 40.09B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
270.19 | 35.67B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
233.25 | 27.44B | 3.81B | -644.79M | -669.77M | -6.24 |
Ionis Pharmaceuticals Inc Stock (IONS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-07 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-03-31 | Eingeleitet | Redburn Atlantic | Neutral |
| 2024-08-02 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2024-07-24 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-07-16 | Fortgesetzt | Jefferies | Buy |
| 2024-06-14 | Hochstufung | Bernstein | Underperform → Mkt Perform |
| 2024-04-10 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2024-01-02 | Hochstufung | BofA Securities | Neutral → Buy |
| 2023-10-23 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2023-09-29 | Eingeleitet | Raymond James | Strong Buy |
| 2023-07-31 | Hochstufung | Citigroup | Neutral → Buy |
| 2023-06-07 | Fortgesetzt | Piper Sandler | Overweight |
| 2023-05-04 | Hochstufung | Citigroup | Sell → Neutral |
| 2023-03-21 | Eingeleitet | Bernstein | Underperform |
| 2022-12-21 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2022-09-09 | Fortgesetzt | Morgan Stanley | Overweight |
| 2022-07-18 | Fortgesetzt | Oppenheimer | Outperform |
| 2022-03-31 | Fortgesetzt | Piper Sandler | Overweight |
| 2022-03-01 | Eingeleitet | Citigroup | Sell |
| 2022-03-01 | Eingeleitet | Guggenheim | Buy |
| 2022-02-01 | Herabstufung | BofA Securities | Buy → Underperform |
| 2021-12-14 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2021-05-07 | Hochstufung | UBS | Sell → Neutral |
| 2021-03-01 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2020-12-16 | Eingeleitet | UBS | Sell |
| 2020-12-15 | Hochstufung | Cowen | Market Perform → Outperform |
| 2020-09-14 | Fortgesetzt | JP Morgan | Neutral |
| 2020-09-02 | Eingeleitet | The Benchmark Company | Hold |
| 2020-06-01 | Fortgesetzt | Oppenheimer | Outperform |
| 2020-05-13 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2020-03-05 | Eingeleitet | Citigroup | Buy |
| 2019-12-13 | Eingeleitet | Oppenheimer | Outperform |
| 2019-11-13 | Eingeleitet | BofA/Merrill | Buy |
| 2019-11-07 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2019-09-10 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2018-08-08 | Bestätigt | Stifel | Hold |
| 2018-08-07 | Bestätigt | Stifel | Hold |
| 2018-05-08 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2017-10-06 | Fortgesetzt | Goldman | Sell |
| 2017-08-17 | Eingeleitet | Evercore ISI | Outperform |
| 2017-08-09 | Bestätigt | Stifel | Hold |
| 2017-03-10 | Herabstufung | Goldman | Neutral → Sell |
| 2016-12-28 | Bestätigt | BMO Capital Markets | Outperform |
| 2016-12-27 | Bestätigt | Leerink Partners | Mkt Perform |
Alle ansehen
Ionis Pharmaceuticals Inc Aktie (IONS) Neueste Nachrichten
Ionis Pharmaceuticals, Inc. (IONS): Among Billionaire Glenn Russell Dubin’s Stock Picks with Huge Upside Potential - Insider Monkey
Billionaire Glenn Russell Dubin’s 10 Stock Picks with Huge Upside Potential - Insider Monkey
Bennett C. Frank of Ionis Pharmaceuticals sells $222,113 in stock - MSN
Angioedema Clinical Trial Pipeline Analysis Demonstrates 15+ Key Companies at the Horizon Expected to Transform the Treatment Paradigm, Assesses DelveInsight - Yahoo Finance
Ionis to host 2025 virtual Annual Meeting of Stockholders | IONS Stock News - GuruFocus
Ionis to host 2025 virtual Annual Meeting of Stockholders - Quantisnow
Spinocerebellar Ataxias Pipeline 2025: Comprehensive Clinical Trials and Therapies Analysis with Key MOA and ROA Insights by DelveInsight | Biogen Inc, BioXcel Corp, Celavie Biosciences, Ionis Pharma - Barchart.com
Spinocerebellar Ataxias Pipeline 2025: Comprehensive - openPR.com
Oligonucleotide Delivery System Market Key Players Analysis - openPR.com
Analysts Just Made A Sizeable Upgrade To Their Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Forecasts - Yahoo Finance
Ionis Pharmaceuticals targets $750M revenue for 2025 with multiple launches underway - MSN
Ionis Q1 Earnings and Sales Top Estimates, Stock Gains on Raised '25 View - MSN
Director Hayden Michael R bought $477,900 worth of shares (15,000 units at $31.86), increasing direct ownership by 43% to 50,219 units (SEC Form 4) - Quantisnow
Ionis Pharmaceuticals First Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
Analysts Just Shipped A Substantial Upgrade To Their Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Estimates - simplywall.st
Press Release Distribution & PR Platform - ACCESS Newswire
Earnings call transcript: Ionis Pharmaceuticals beats Q1 2025 forecasts - Investing.com Australia
Ionis Pharmaceuticals (IONS) Projects Revenue Growth with TRYNGO - GuruFocus
Ionis Pharmaceuticals (IONS) Reports Q1 Loss, Tops Revenue Estimates - MSN
IONIS: Guggenheim Maintains Buy Rating but Lowers Price Target | - GuruFocus
Ionis Pharmaceuticals (IONS) Receives Price Target Boost from HC Wainwright | IONS Stock News - GuruFocus
Ionis Pharmaceuticals (IONS) Target Price Adjusted by Guggenheim - GuruFocus
Polycythemia vera Market: Epidemiology, Therapies, - openPR.com
Ionis Earnings: Strong Commercial Launch of Tryngolza; Positive Long-Term Outlook - Morningstar
The Analyst Verdict: Ionis Pharmaceuticals In The Eyes Of 13 Experts - Benzinga
Ionis Pharmaceuticals (IONS) Target Price Increased to $50 After Strong Q1 | IONS Stock News - GuruFocus
Ionis Pharmaceuticals Ups Revenue Forecast After Q1 Success - Finimize
Ionis Pharmaceuticals Lifts Revenue Forecast After Strong Q1, Oppenheimer Says - marketscreener.com
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Q1 2025 Earnings Call Transcript - Insider Monkey
Ionis Pharmaceuticals (IONS) Target Price Adjusted by Guggenheim | IONS Stock News - GuruFocus
Ionis Pharmaceuticals Inc (IONS) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and ... - Yahoo Finance
Ionis Pharmaceuticals Inc (IONS) Q1 2025 Earnings Call Highlight - GuruFocus
Ionis Pharmaceuticals Inc (IONS) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and ... By GuruFocus - Investing.com Canada
Ionis Pharmaceuticals Reports Strong Q1 2025 Results - TipRanks
Ionis Pharmaceuticals: Q1 Earnings Snapshot - MySA
Ionis Pharmaceuticals’ Earnings Call Highlights Growth Amid Challenges - TipRanks
Ionis Pharmaceuticals Q1 2025 Earnings Call Transcript - MarketBeat
Ionis Pharmaceuticals (IONS) Boosts 2025 Revenue Guidance and St - GuruFocus
Ionis Pharmaceuticals Narrows Q1 Loss, Lifts Revenue Forecast While Drug Sales Surge - Benzinga
Earnings call transcript: Ionis Pharmaceuticals beats Q1 2025 forecasts By Investing.com - Investing.com India
Novartis to acquire Regulus in deal for kidney disease drug - BioPharma Dive
Ionis Pharmaceuticals (IONS) Q1 2025 Earnings: Revenue Surpasses - GuruFocus
Ionis Pharmaceuticals Reports First Quarter 2025 Financial Results - TradingView
Ionis Pharmaceuticals Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Ionis Pharmaceuticals (IONS) Reports Q1 Earnings: What Key Metrics Have to Say - Yahoo Finance
Ionis Pharmaceuticals Q1 Net Loss Narrows as Revenue Increases; 2025 Revenue Guidance Raised - marketscreener.com
Ionis (IONS) Sees Strong Q1 Revenue with New Launches Fueling Gr - GuruFocus
Ionis reports first quarter 2025 financial results - BioSpace
Finanzdaten der Ionis Pharmaceuticals Inc-Aktie (IONS)
Umsatz
Nettogewinn
Free Cashflow
ENV
Ionis Pharmaceuticals Inc-Aktie (IONS) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Birchler Brian | EVP, Corp and Development Ops |
Apr 15 '25 |
Option Exercise |
0.00 |
1,875 |
0 |
57,340 |
| Birchler Brian | EVP, Corp and Development Ops |
Apr 16 '25 |
Sale |
28.37 |
680 |
19,292 |
56,660 |
| Jenne Kyle | EVP, Chf GL Pdt Str Ofcr |
Apr 15 '25 |
Option Exercise |
0.00 |
12,226 |
0 |
14,215 |
| Jenne Kyle | EVP, Chf GL Pdt Str Ofcr |
Apr 16 '25 |
Sale |
28.36 |
3,016 |
85,534 |
11,199 |
| Baroldi Joseph | EVP, Chief Business Officer |
Apr 15 '25 |
Option Exercise |
0.00 |
10,837 |
0 |
35,854 |
| Baroldi Joseph | EVP, Chief Business Officer |
Apr 16 '25 |
Sale |
28.40 |
3,928 |
111,555 |
31,926 |
4.10%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):